Search 

BalinBac Therapeutics, Inc. is a clinical stage biopharmaceutical development company headquartered in Princeton, New Jersey, focused on rapidly bringing both repurposed and new antivirals and antibiotics to market. BalinBac started working on coronavirus drug solutions in January 2020 when the team predicted the impact of the COVID-19 pandemic.

Our scientists and therapeutics development executives have a wealth of working knowledge in the pharmaceutical industry and have a track record of successfully bringing key antiviral and antibacterial drugs to market. We know how to rapidly get drugs to patients and what it takes to get this work done quickly.

At Biolingus, we believe we can make life better for many people in the world, not just in rich countries, but across the globe.
BioLingus is an award-winning Swiss biotech company spearheading the development of oral (sublingual) and mucosal delivery of peptides and proteins. Our technology is "inspired by nature" using applied bio-engineering, resulting in novel bio-mimetic materials for drug delivery. Our company focusses on the development of its own products on the treatment of chronic diseases, such as diabetes, obesity and inflammatory diseases.
BioLingus’ main office is in Switzerland, with satellite companies in Hong Kong and Australia.
See also video made by the Swiss Chinese Chamber of Commerce : https://www.linkedin.com/posts/yvesdecadt_icbc-vischer-gunvor-activity-6737745258496434176-8BZc

Canadian IVD company with core competencies in the fields of Thrombosis, Haemostasis and oncology, with innovative technologies, we collaborate internationally with technology development companies and health-care stakeholders to develop and manufacture customized reagents and diagnostic solutions.

Who We Are

An executive search and talent acquisition specialist with a wealth of experience in the life science business sector
An alternative to the generalist search firms that offer only general search services
Able to find the right talent for you with the right approach and understanding the complexity of the life science industry
Able to build pools helping our clients to attract a long term and sustainable talent pipeline for current and future requirements, placing your company ahead of competition

Bioxis, creates biomaterial scaffolds that help regenerate tissues, improve patient outcomes, and provide better healthcare opportunities for doctors. We are focused on developing medical devices based on patented biomaterials technology with potentially accelerated pathways to the aesthetic dermatology market.

Our lead medical device candidate MTI-12 is currently at the pre-clinical stage for aesthetic indications; and our hyaluronic acid-based dermal filler brand, CYTOSIAL, has established into exclusive distribution agreements with distributors in Europe and Asia.

Calciscon develops and markets diagnostic devices for the assessment of calcification- and cardiovascular risk to improve disease management of kidney patients worldwide. Our flagship product T50 is the only test capable of accurately predicting the prognosis of a kidney patient. Across 30+ peer-reviewed studies, T50 was demonstrated to accurately predict progression of vascular calcification, cardiovascular events and death. T50 is the only reliable test to individualize the treatment modality of kidney patient to improve prognosis.

CarthaGenetics® provides consulting services to rare diseases, advanced therapies, and orphan drugs companies who want to step in the complex European markets (including Turkey) and the fast-growing North African markets. CarthaGenetics® was founded in 2004 by Philippe Carteron, on the basis of his personal commitment to the treatment of orphan diseases (rare & mostly genetic diseases) across Western Europe, Turkey & North Africa.
CarthaGenetics® has worked for the most prestigious biotech and pharma companies, as Alexion, Alnylam, Amicus, Biogen, BioMarin, FoldRX/Pfizer, Genzyme, Horizon, Insmed, Orchard, PTC, RegenXbio, Shire, Ultragenyx, as well as for Turkish Ministry of Health and Turkish Pharmacist Association (TEB). CarthaGenetics® is focused on innovative medicines, including cell and gene therapies and has 3 main areas of expertise:

1) Speed up the enrollment in Clinical Trial(s) through patient identification in cooperation with CROs:
- Our direct presence in countries with high birth numbers as Turkey, Algeria, Tunisia, Morocco is increasing the chances to complete enrollment in a shorter time.
- Our strong network among Pediatricians, Metabolicians, (Pediatric) Neurologists, Lipidologists, (Pediatric) Nephrologists, Geneticists, Hematologists and Oncologists will speed up patients identification.

2) Early Access Program (EAP or NPP) including Compassionate Use and Named Patient Sales (NPS) in countries where such programs are allowed as for instance:
- ATU in France
- Law 648 / Law 326 in Italy
- Endikasyon Dışı Kullanım Kılavuzu in Turkey

3) Biosimilars of Orphan Drugs for North Africa where there is no Orphan Drug exclusivity, representing a population about 100M. For any question please send us a message on contact@carthagenetics.com or contact us at our Swiss Headquarter +41 22 575 31 31 and visit our website at www.carthagenetics.com

CarthaGenetics® is directly present in Switzerland, France, Germany, Italy, Spain, Turkey as well as in Algeria and Tunisia

Cell4Pharma BV is a Dutch Bio-tech company that produces and commercializes human renal proximal tubule epithelial cell lines to perform in vitro toxicology assessments, with the aim to eliminate renal toxicity for compounds entering clinical stages of drug development; Cell4Pharma aims to lower drug failure during the clinical phase of drug development due to kidney toxicity.
To get more successful drugs to market, we empower researchers to accurately identify and eliminate nephro-toxic compounds during preclinical stages of drug development. We partner with CRO's to deliver our highly accurate and stable human renal ciPTEC Cell Lines to researchers of Bio-pharmaceutical companies and Academia